Raymond James Maintains Outperform Rating for Rocket Pharmaceuticals: Here's What You Need To Know

Raymond James Maintains Outperform Rating for Rocket Pharmaceuticals: Here's What You Need To Know

 

Raymond James has decided to maintain its Outperform rating of Rocket Pharmaceuticals RCKT and raise its price target from $22.00 to $24.00.

Shares of Rocket Pharmaceuticals are trading up 2.46% over the last 24 hours, at $16.23 per share.

A move to $24.00 would account for a 47.87% increase from the current share price.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Posted In: BZI-AAR-UPDATEAnalyst Ratings